Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15564536 | 0.86 | NR1H2 (0.33) | NR1H2NR1H3TSHRESR1ESR2 | |
| SCHEMBL8701181 | 0.83 | CYP2C19 (0.38) | NR1H2NR1H3TSHRESR1ESR2 | |
| SCHEMBL30821468 | 0.82 | KCNH3 (0.36) | TSHRALDH1A1RECQL | |
| SCHEMBL9475415 | 0.81 | MAPT (0.31) | NR1H2NR1H3TSHRMAPT | |
| SCHEMBL6312176 | 0.80 | TSHR (0.34) | NR1H2NR1H3TSHRESR1ESR2 | |
| SCHEMBL8056864 | 0.79 | MAPT (0.33) | NPC1RAB9AMAPTCYP2C19HIF1A | |
| SCHEMBL6675595 | 0.79 | CYP2C19 (0.40) | TSHRESR1ESR2NPC1RAB9A | |
| SCHEMBL29967632 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL8878189 | 0.76 | HDAC3 (0.43) | TSHRMAPTNPSR1CYP2C19HIF1A | |
| SCHEMBL14770816 | 0.76 | TP53 (0.35) | TSHRESR1ESR2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| US-10640526-B2 | Method of preparation of 6-azido-2,4-diacetamido-2,4,6-trideoxy-D-mannose | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-05 | — | — | US | disclosed |
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3468599-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2370422-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010056767-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-6143724-A | USED FOR TREATMENT, IMPROVEMENT AND PREVENTION OF INFLAMMATION AND DISEASES ACCOMPANYING INFLAMATION | DAIKIN INDUSTRIES, LTD. (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-1013660-A1 | 2-FLUOROFUCOSYL-N-AROYLGLUCOSAMINE DERIVATIVES, INTERMEDIATES THEREFOR, AND PROCESSES FOR PRODUCING THESE | Daikin Industries, Limited (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | NR1H2 3081/4885NR1H3 3132/4885TSHR 2901/4885 |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NR1H2 3380/4885NR1H3 3120/4885TSHR 719/4885 |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | NR1H2 3994/4885NR1H3 3224/4885TSHR 1889/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NR1H2 3380/4885NR1H3 3120/4885TSHR 719/4885 |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | NR1H2 1566/4885NR1H3 1121/4885TSHR 3108/4885 |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | NR1H2 405/4885NR1H3 493/4885TSHR 1678/4885 |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | NR1H2 1566/4885NR1H3 1121/4885TSHR 3108/4885 |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | NR1H2 2331/4885NR1H3 1527/4885TSHR 1136/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | NR1H2 3081/4885NR1H3 3132/4885TSHR 2901/4885 |
| US-10640526-B2 | Method of preparation of 6-azido-2,4-diacetamido-2,4,6-trideoxy-D-mannose | ST6GAL1, B4GALT1, GALNT6 | NR1H2 2056/4885NR1H3 1811/4885TSHR 191/4885 |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | NR1H2 405/4885NR1H3 493/4885TSHR 1678/4885 |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | NR1H2 3380/4885NR1H3 3120/4885TSHR 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.